Antiviral Drugs Market Analysis By Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitor, Protease Inhibitor), By Application (HIV, Hepatitis, HSV, Influenza), By Type (Generic, Branded) And Segment Forecast 2014-2025

  • ID: 4118838
  • Report
  • 85 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie
  • Aurobindo Pharma
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche AG
  • Gilead Sciences
  • MORE

The global antiviral drugs market is expected to reach a value of USD 69.2 billion by 2025. According to the WHO, cases of viral infections increase by more than 1 million each year with around 357 million patients already suffering from one of the four Sexually Transmitted Infections (STIs), such as Acquired Immunodeficiency Syndrome (AIDS).

Introduction of efficient antiviral drugs with benefits such as rapid action, increased sensitivity, and lower adverse effects is expected to serve this market as a high-impact rendering driver over the forecast period. For instance, Gilead Sciences introduced an FDA-approved drug-Genvoya-in 2016 for treatment of AIDS patients who have previously faced adverse effects, such as bone loss and kidney dysfunction.

Low levels of hygiene, growing geriatric population, and increasing awareness through government campaigns are other drivers resulting in high acceptance of antiviral drugs in developing countries.

Further Key Findings From the Study Suggest:

Reverse transcriptase inhibitors held the largest share by mechanism of action owing to availability of wide range of product portfolio and presence of new molecules in clinical trials

Nucleotide inhibitors are estimated to grow at lucrative rate due to introduction of blockbuster molecules for treatment of Hepatitis C Virus (HCV) infections

Generic drugs are anticipated to witness significant CAGR of over 7.0% over the forecast period as result of patent expiry of blockbuster drugs used for treatment of HIV and HCV

Branded drugs will hold dominant position in 2025 by drug type due to brand loyalty of healthcare professions despite patent expiration and high price associated with these molecules

HIV/AIDS held the dominant share in 2015. High prevalence of HIV infections and presence of favorable government initiatives for curbing them are key factors for high revenue of this segment

Hepatitis on the other hand is anticipated to witness flourishing growth over the forecast period owing to introduction of new molecules and approval of novel combination treatments

North America was the dominant regional market in 2015. High market share is associated with established R&D infrastructure and growing drug development initiatives

Asia Pacific region is anticipated to exhibit fastest regional growth. Local presence of key generic players and growing healthcare infrastructure in this region are key factors for growth

Some of the key players of this market include Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline; Bristol-Myers-Squibb; AbbVie; Johnson & Johnson; and Merck & Co. Other generic players in this market are Aurobindo Pharma, Cipla, and Dr Reddy’s


PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Aurobindo Pharma
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche AG
  • Gilead Sciences
  • MORE

1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 Internal Database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
2 Executive Summary
2.1 Market Snapshot
3 Antiviral Drugs Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.1.1 Market Driver Analysis
3.1.1.1 Growing geriatric population base
3.1.1.2 Growing prevalence of target diseases
3.1.1.3 Increasing R&D expenditure
3.1.2 Market restraint analysis
3.1.2.1 High cost
3.1.3 Stringent regulatory scenario
3.2 Penetration & growth prospect mapping
3.3 Antiviral Drugs- SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
4 Antiviral Drugs Market: Mechanism of Action Estimates & Trend Analysis
4.1 Antiviral drugs market: Mechanism of action movement analysis
4.2 Nucleotide polymerase inhibitor
4.2.1 Nucleotide polymerase inhibitor market, 2014 - 2025 (USD Billion)
4.3 Reverse transcriptase inhibitors
4.3.1 Reverse transcriptase inhibitors market, 2014 - 2025 (USD Billion)
4.4 Protease inhibitors
4.4.1 Protease inhibitors market, 2014 - 2025 (USD Billion)
4.5 Others
4.5.1 Others market, 2014 - 2025 (USD Billion)
5 Antiviral Drugs Market: Type Estimates & Trend Analysis
5.1 Antiviral drugs market: Type movement analysis
5.2 Generic drugs
5.2.1 Generic drugs market, 2014 - 2025 (USD Billion)
5.3 Branded drugs
5.3.1 Branded drugs market, 2014 - 2025 (USD Billion)
6 Antiviral Drugs Market: Application Estimates & Trend Analysis
6.1 Antiviral drugs market: Application movement analysis
6.2 HIV
6.2.1 HIV market, 2014 - 2025 (USD Billion)
6.3 Hepatitis market
6.3.1 Hepatitis market market, 2014 - 2025 (USD Billion)
6.4 Herpes virus
6.4.1 Herpes virus market, 2014 - 2025 (USD Billion)
6.5 Influenza
6.5.1 Influenza market, 2014 - 2025 (USD Billion)
6.6 Others
6.6.1 Others market, 2014 - 2025 (USD Billion)
7 Antiviral Drugs Market: Regional Estimates & Trend Analysis, by Application
7.1 Antiviral drugs market share by region, 2015 & 2025
7.2 North America
7.2.1 North America antiviral drugs market, 2014 - 2025 (USD Billion)
7.2.2 U.S
7.2.2.1 U.S antiviral drugs market, 2014 - 2025 (USD Billion)
7.2.3 Canada
7.2.3.1 Canada antiviral drugs market, 2014 - 2025 (USD Billion)
7.3 Europe
7.3.1 Europe antiviral drugs market, 2014 - 2025 (USD Billion)
7.3.2 UK
7.3.2.1 UK antiviral drugs market, 2014 - 2025 (USD Billion)
7.3.3 Germany
7.3.3.1 Germany antiviral drugs market, 2014 - 2025 (USD Billion)
7.4 Asia Pacific
7.4.1 Asia Pacific antiviral drugs market, 2014 - 2025 (USD Billion)
7.4.2 Japan
7.4.2.1 Japan antiviral drugs market, 2014 - 2025 (USD Billion)
7.4.3 China
7.4.3.1 China antiviral drugs market, 2014 - 2025 (USD Billion)
7.4.4 India
7.4.4.1 India antiviral drugs market, 2014 - 2025 (USD Billion)
7.5 Latin America
7.5.1 Latin America antiviral drugs market, 2014 - 2025 (USD Billion)
7.5.2 Brazil
7.5.2.1 Brazil antiviral drugs market, 2014 - 2025 (USD Billion)
7.5.3 Mexico
7.5.3.1 Mexico antiviral drugs market, 2014 - 2025 (USD Billion)
7.6 MEA
7.6.1 MEA antiviral drugs market, 2014 - 2025 (USD Billion)
7.6.2 South Africa
7.6.2.1 South Africa antiviral drugs market, 2014 - 2025 (USD Billion)
8 Competitive Landscape
8.1 Strategy Framework
8.2 Market Participation Categorization
8.3 Company Profiles
8.3.1 Gilead Sciences
8.3.1.1 Company overview
8.3.1.2 Financial performance
8.3.1.3 Product benchmarking
8.3.1.4 Strategic initiatives
8.3.2 F. Hoffmann-La Roche AG
8.3.2.1 Company overview
8.3.2.2 Financial performance
8.3.2.3 Product benchmarking
8.3.2.4 Strategic initiatives
8.3.3 GlaxoSmithKline
8.3.3.1 Company overview
8.3.3.2 Financial performance
8.3.3.3 Product benchmarking
8.3.3.4 Strategic initiatives
8.3.4 Bristol-Myers-Squibb
8.3.4.1 Company overview
8.3.4.2 Financial performance
8.3.4.3 Product benchmarking
8.3.4.4 Strategic initiatives
8.3.5 AbbVie
8.3.5.1 Company overview
8.3.5.2 Financial performance
8.3.5.3 Product benchmarking
8.3.5.4 Strategic initiatives
8.3.6 Johnson and Johnson
8.3.6.1 Company overview
8.3.6.2 Financial overview
8.3.6.3 Product benchmarking
8.3.6.4 Strategic initiatives
8.3.7 Aurobindo Pharma
8.3.7.1 Company overview
8.3.7.2 Financial overview
8.3.7.3 Product benchmarking
8.3.7.4 Strategic initiatives
8.3.8 Mylan N.V.
8.3.8.1 Company overview
8.3.8.2 Financial overview
8.3.8.3 Product benchmarking
8.3.8.4 Strategic initiatives
8.3.9 Merck & Co
8.3.9.1 Company overview
8.3.9.2 Financial overview
8.3.9.3 Product benchmarking
8.3.9.4 Strategic initiatives
8.3.10 Cipla
8.3.10.1 Company overview
8.3.10.2 Financial overview
8.3.10.3 Product benchmarking
8.3.10.4 Strategic initiatives
8.3.11 Dr. Reddy’s Laboratories Ltd
8.3.11.1 Company overview
8.3.11.2 Financial overview
8.3.11.3 Product benchmarking
8.3.11.4 Strategic initiatives

List of Tables

Table 1 Country share estimation
Table 2 North America antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 3 North America antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 4 North America antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 5 U.S. antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 6 U.S. antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 7 U.S. antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 8 Canada antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 9 Canada antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 10 Canada antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 11 Europe antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 12 Europe antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 13 Europe antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 14 UK antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 15 UK antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 16 UK antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 17 Germany antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 18 Germany antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 19 Germany antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 20 Asia Pacific antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 21 Asia Pacific antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 22 Asia Pacific antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 23 Japan antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 24 Japan antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 25 Japan antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 26 China antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 27 China antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 28 China antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 29 India antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 30 India antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 31 India antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 32 Latin America antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 33 Latin America antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 34 Latin America antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 35 Brazil antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 36 Brazil antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 37 Brazil antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 38 Mexico antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 39 Mexico antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 40 Mexico antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 41 MEA antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 42 MEA antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 43 MEA antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion)
Table 44 South Africa antiviral drugs market estimates and forecasts, by mechanism of action, 2014 - 2025 (USD Billion)
Table 45 South Africa antiviral drugs market estimates and forecasts, by type, 2014 - 2025 (USD Billion)
Table 46 South Africa antiviral drugs market estimates and forecasts, by application, 2014 - 2025 (USD Billion) List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Value chain based sizing & forecasting
Figure 4 QFD modeling for market share assessment
Figure 5 Market summary
Figure 6 Market trends &outlook
Figure 7 Market segmentation & scope
Figure 8 Market driver relevance analysis (Current & future impact)
Figure 9 Global percentage of population, by age group, 2050 and 2000
Figure 10 Market restraint relevance analysis (Current & future impact)
Figure 11 Penetration & growth prospect mapping
Figure 12 SWOT Analysis, By Factor (political & legal, economic and technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Antiviral Drugs market mechanism of action outlook key takeaways
Figure 15 Antiviral drugs market: Mechanism of action movement analysis
Figure 16 Global Nucleotide polymerase inhibitor market, 2014 - 2025 (USD Billion)
Figure 17 Global Reverse transcriptase inhibitors market, 2014 - 2025 (USD Billion)
Figure 18 Global Protease inhibitors market, 2014 - 2025 (USD Billion)
Figure 19 Global vaccines market, 2014 - 2025 (USD Billion)
Figure 20 Antiviral drugs market type outlook key takeaways
Figure 21 antiviral drugs market: Type of Manufacturer movement analysis
Figure 22 Global Generic drugs market, 2014 - 2025 (USD Billion)
Figure 23 Global branded drugs market, 2014 - 2025 (USD Billion)
Figure 24 Antiviral drugs market application outlook key takeaways
Figure 25 Antiviral drugs market: Application movement analysis
Figure 26 Global HIV market, 2014 - 2025 (USD Billion)
Figure 27 Global hepatitis market market, 2014 - 2025 (USD Billion)
Figure 28 Global Herpes virus market, 2014 - 2025 (USD Billion)
Figure 29 Global Influenza market, 2014 - 2025 (USD Billion)
Figure 30 Global Others market, 2014 - 2025 (USD Billion)
Figure 31 Regional market place: Key takeaways
Figure 32 Regional outlook, 2015 & 2024
Figure 33 North America antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 34 U.S. antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 35 Canada antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 36 Europe antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 37 UK antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 38 Germany antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 39 Asia Pacific antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 40 Japan antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 41 China antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 42 India antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 43 Latin America antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 44 Brazil antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 45 Mexico antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 46 MEA antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 47 South Africa antiviral drugs market, 2014 - 2025 (USD Billion)
Figure 48 Strategy framework
Figure 49 Participant categorization

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Gilead Sciences
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline
  • Bristol-Myers-Squibb
  • AbbVie
  • Johnson and Johnson
  • Aurobindo Pharma
  • Mylan N.V.
  • Merck & Co
  • Cipla
  • Dr. Reddy’s Laboratories Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll